Share on LinkedInShare on LinkedIn

ARTICLE · 05 NOVEMBER 2013

Norvatis Says Indian Supreme Court Discourages Innovation

India’s Supreme Court does not allow cancer drug, Glivec, patent protection.

IndiaIntellectual Property
Bredenkamp Attorneys
Bredenkamp Attorneys

India's Supreme Court does not allow cancer drug, Glivec, patent protection. In response, Novartis said that this "discourages future innovation in India".

Glivec (imatinib mesylate) is recognized as a life-saving cancer drug. Patents for Glivec have already been granted in China, Russia and Taiwan. A patent was denied in India on the grounds that the crystalline structure of the mesylate salt of imatinib was a new form of a known substance.

A lot of controversy surrounds this matter. Some critics say that a statement by Novartis that it provides Glivec free of charge to 0.95% of Indian patients is skewed and deceiving. Activists see the verdict as a victory for patients' right to cheap medicines.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from